A double-blind clinical comparison of Hexabrix and Renografin-76 for intravenous digital subtraction angiography.
A double-blind comparison of Hexabrix and Renografin-76 for intravenous digital subtraction angiography (IV-DSA) revealed a slightly greater percentage of patients with good or satisfactory examinations who received Hexabrix. There were fewer perturbations of the ECG, less alteration in the diastolic blood pressure, and no serious adverse reactions noted in the Hexabrix group. However, the differences between the groups were not statistically significant. When used for IV-DSA, the lower osmolality associated with Hexabrix offers the theoretic advantages of (1) reduced osmotic load and (2) diminished alteration in central blood volume.
D000328:Adult; D000368:Aged; D000703:Analog-Digital Conversion; D000792:Angiography / Q000379:methods*; D002986:Clinical Trials as Topic; D003287:Contrast Media; D003973:Diatrizoate / Q000031:analogs & derivatives*; D003974:Diatrizoate Meglumine; D004311:Double-Blind Method; D004338:Drug Combinations; D004562:Electrocardiography; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007463:Iodobenzoates; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D013382:Subtraction Technique; D014283:Triiodobenzoic Acids
D003287:Contrast Media; D004338:Drug Combinations; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D003973:Diatrizoate; D003974:Diatrizoate Meglumine; C027278:urovision; D007485:Ioxaglic Acid